Tell Gilead to Reduce the Cost of HIV Medications Now!
By Kevin Maloney
March 5, 2012
Referencing the latest figure from the National Alliance of State and Territorial AIDS Directors (NASTAD), as of February 23, 2012, 4,251 individuals across 11 states are on the AIDS Drug Assistance Program (ADAP) waitlist. These are individuals who are uninsured or underinsured who have received an HIV+ diagnosis, and are unable to properly attain the drugs they need to remain alive, healthy and productive.
In support of the following letter sent to Gilead from the Fair Pricing Coalition, and signed by individual members, the FPC outlines its concerns, and requests specific actions be taken by Gilead. Any interested individual or organization is welcomed, and encouraged to sign on. Please share WIDELY across your networks:
It is essential that Gilead understand the negative impact of their actions on people living with HIV/AIDS (PLWHAs). Since 2009, Gilead has raised prices three times each for Viread and Truvada for a total of 22.1% and 24.5% respectively; twice for Emtriva for a total of 15.3%,and agreed to four price increases on for Atripla, totaling 21%, and agreed to a 7.3% price increase for Complera. These increases are dramatically higher than the rate of inflation. They also come at a time when many people with HIV have lost their jobs, their employer-based insurance coverage and, in many instances, their ADAP coverage, all resulting in desperate patients attempting to access HIV drugs on the open market, a market plagued with constantly increasing drug prices.
As U.S. economic stagnation persists, PLWHAs continue to lose jobs, income, health care benefits and ADAP coverage. At the same time, third party payers are imposing higher premiums as a direct result of escalating drug prices. Some patients have abruptly stopped treatment because they can no longer afford their medications. Although PAPs exist to help people who cannot afford medication, barriers to access are significant. Many people are unaware of the existence of PAPs. Others cannot cope with the labyrinth of multiple forms and requirements. Even with Gilead's PAP eligibility at 500% of the Federal Poverty Level, a PLWHA earning $56,000.00 annually is not PAP eligible and will have to pay $20,000.00 or more to purchase Atripla at retail prices. This figure represents at least two-thirds of their net income.
The pharmaceutical industry's extravagant price increases reverberate throughout the healthcare industry. They come at a time when many ADAPs are covering private insurance payments for their clients and result in ADAPs paying significantly increased premiums as a result of exorbitant price increases. This policy also results in higher premiums for people with HIV who are insured at a time when more and more people have less and less income due to unemployment, underemployment, reduced wages and reduced hours. Moreover, higher healthcare costs mean higher co-pays and pharmacy deductibles for people with private insurance and high share-of-cost plans which also result in increased costs to patients as well as decreased benefits. More restrictive access within insurance plans affects the cost of drugs, but also ancillary services, such as mental health, prevention healthcare, rehabilitation and substance abuse services.
Escalating costs for private and employee healthcare plans occasioned by continuous drug pricing increases will undoubtedly have a deleterious effect on the states as they design their health care exchanges in preparation for the 2014 implementation of the Affordable Care Act (ACA). Many states are likely to set a minimum standard for drug coverage for their "essential health benefits" package that requires only limited coverage of antiretrovirals and other higher cost drug classes. Additionally, with non-preferred generic antiretrovirals entering the marketplace we are concerned that higher drug prices will increasingly result in key coverage decisions being driven by cost rather than the standard of care for HIV treatment.
Much of this crisis is occasioned by irresponsible pharmaceutical industry behavior. We firmly believe that Gilead's price increases are particularly egregious because Gilead currently has the lion's share of the antiretroviral market.
We believe that the best way to begin to address these issues is for industry to change its price increase practices and agree to the following:
Now is the time for Gilead to reconsider its price increase policy and rescind its latest unreasonable price increases. The FPC, its members and the undersigned sincerely hope that Gilead will agree to the above and we look forward to your immediate response.
The ADAP Recertification Process; the Frustration Mounts! Important: Make Sure All Your Contact Info Is Up to Date!
Rising Up and Speaking Out About HIV and Hepatitis C
Random things about me: I am kind, caring, respectful and wanting to make a difference/impact in the World. I've been to Australia, New Zealand and 13 countries in Europe, and have traveled and lived all over the United States. I have a Bachelor's degree in Health Services Management and will be working towards my Master's In Public Health. I am an uncle of two of the MOST adorable girls in the World, and have one brother. I am a Momma's boy, and it is hard to see my mother's health in such a deteriorated state -- she has severe COPD (from 40 years of smoking). In March 2010 I was told that I have HIV and a month later, with follow-up labs, was then told I also acquired hepatitis C (not through IV drug use). I aspire to great things. Stay tuned.
Subscribe to Kevin's Blog:
January 23, 2013 - Take a Photo and Be Part of the "No Shame About Being HIV Positive" Campaign! A Blog Entry by Kevin Maloney
September 21, 2012 - Contest: Write a Poem About HIV/AIDS and/or Hepatitis C and Win a Gift Card of Your Choice -- A Blog Entry by Kevin Maloney
August 26, 2012 - A Letter From My Dad Regarding Life Challenges, My New Career Path and My Recent Award: A Blog Entry by Kevin Maloney
April 26, 2012 - Join the Campaign to Trend #HIV #AIDS and #IAC on Twitter During the International AIDS Conference: A Blog Entry by Kevin Maloney
March 5, 2012 - Tell Gilead to Reduce the Cost of HIV Medications Now! A Blog Entry by Kevin Maloney
A Brief Disclaimer:
The opinions expressed by TheBody.com's bloggers are entirely their own, and do not necessarily reflect the views of TheBody.com itself.